Thelansis

 Autoimmune Hepatitis (AIH) is a rare liver disorder characterized by immune-mediated inflammation of the liver, which can manifest as acute or chronic inflammation. Clinically, it often appears as cryptogenic hepatitis and is identified by interface hepatitis upon histological examination. Patients typically exhibit elevated serum aminotransferase levels and increased levels of immunoglobulin G (IgG) or hypergammaglobulinemia, either with or without specific circulating autoantibodies. Patients with AIH may display various symptoms, from being asymptomatic to experiencing chronic illness or acute liver failure. It is not uncommon for individuals with AIH to have concurrent autoimmune diseases. This disease can affect pediatric and adult patients, and its presentation varies widely. About 25% of patients experience an acute onset or an acute-on-chronic disease course. Some individuals have a severe form of the disease at diagnosis, which can quickly progress to liver failure. The m...

  Autoimmune hepatitis (AIH) is a type of liver inflammation that occurs when your immune system attacks liver cells. Although the exact cause of autoimmune hepatitis is unknown, but genetic and environmental factors appear to interact over time to cause the disease. Untreated autoimmune hepatitis can result in liver scarring (cirrhosis) and, eventually to liver failure. When diagnosed and treated early, autoimmune hepatitis can often be controlled with immune-suppressing drugs. When drug treatments for autoimmune hepatitis fail or in cases of advanced liver disease, a liver transplant may be an option. The incidence of autoimmune hepatitis (AIH) is estimated at 1-2 per 100,000, and the prevalence is approximately 24 per 100,000. Thelansis’s “Autoimmune Hepatitis (AIH) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive land...